Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Provided By GlobeNewswire
Last update: Sep 11, 2023
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend Toward Significance
Read more at globenewswire.comNASDAQ:CINGW (12/19/2025, 8:00:00 PM)
0.055
+0 (+3.77%)
3.97
+0.11 (+2.85%)
Find more stocks in the Stock Screener
